CM
MCID: MLR004
MIFTS: 83

Malaria (CM) malady

Categories: Genetic diseases, Rare diseases, Infectious diseases

Aliases & Classifications for Malaria

Aliases & Descriptions for Malaria:

Name: Malaria 54 38 12 50 56 29 52 41 3 42 14 69
Malaria, Cerebral 54 42 69
Cerebral Malaria 12 14
Induced Malaria 12 69
Malaria, Susceptibility to Malaria, Resistance to, Included 54
Malaria, Vivax, Protection Against 54
Malaria, Cerebral, Reduced Risk of 54
Malaria Due to G6pd Deficiency 54
Malaria, Protection Against 54
Malarial Encephalitis 12
Malaria Cerebral 52
Malaria, Severe 54
Cm 45

Characteristics:

Orphanet epidemiological data:

56
malaria
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 56  
Rare infectious diseases


External Ids:

OMIM 54 611162
Disease Ontology 12 DOID:12365 DOID:14069
ICD10 33 B54 B50.0 B53.1
ICD9CM 35 084 084.6
NCIt 47 C34797
Orphanet 56 ORPHA673
MESH via Orphanet 43 D008288
UMLS via Orphanet 70 C0024530

Summaries for Malaria

OMIM : 54 Malaria, a major cause of child mortality worldwide, is caused by mosquito-borne hematoprotozoan parasites of the genus... (611162) more...

MalaCards based summary : Malaria, also known as malaria, cerebral, is related to hepatitis and tuberculosis, and has symptoms including myalgia, fever and headache. An important gene associated with Malaria is ICAM1 (Intercellular Adhesion Molecule 1), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Artesunate and Quinine have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and brain, and related phenotypes are hematopoietic system and cardiovascular system

Disease Ontology : 12 A parasitic protozoa infectious disease characterized as a vector-borne infectious disease caused by the presence of protozoan parasites of the genus Plasmodium in the red blood cells, transmitted from an infected to an uninfected individual by the bite of anopheline mosquitoes, and characterized by periodic attacks of chills and fever that coincide with mass destruction of blood cells and the release of toxic substances by the parasite at the end of each reproductive cycle.

NIH Rare Diseases : 50 malaria is a serious and sometimes fatal disease caused by a parasite that commonly infects a certain type of mosquito which feeds on humans. infection with malaria parasites may result in a wide variety of symptoms, ranging from absent or very mild symptoms to severe disease and even death. people who get malaria are typically very sick with high fevers, shaking chills, and flu-like illness. in general, malaria is a curable disease if diagnosed and treated promptly and correctly. treatment depends on many factors including disease severity, the species of malaria parasite causing the infection and the part of the world in which the infection was acquired. last updated: 5/12/2011

MedlinePlus : 41 malaria is a serious disease caused by a parasite. you get it when an infected mosquito bites you. malaria is a major cause of death worldwide, but it is almost wiped out in the united states. the disease is mostly a problem in developing countries with warm climates. if you travel to these countries, you are at risk. there are four different types of malaria caused by four related parasites. the most deadly type occurs in africa south of the sahara desert. malaria symptoms include chills, flu-like symptoms, fever, vomiting, diarrhea, and jaundice. a blood test can diagnose it. it can be life-threatening. however, you can treat malaria with drugs. the type of drug depends on which kind of malaria you have and where you were infected. malaria can be prevented. when traveling to areas where malaria is found see your doctor for medicines that protect you wear insect repellent with deet cover up sleep under mosquito netting centers for disease control and prevention

CDC : 3 Malaria is a mosquito-borne disease caused by a parasite. People with malaria often experience fever, chills, and flu-like illness. Left untreated, they may develop severe complications and die. In 2015 an estimated 212 million cases of malaria occurred worldwide and 429,000 people died, mostly children in the African Region. About 1,500 cases of malaria are diagnosed in the United States each year. The vast majority of cases in the United States are in travelers and immigrants returning from countries where malaria transmission occurs, many from sub-Saharan Africa and South Asia.

Wikipedia : 71 Malaria is a mosquito-borne infectious disease affecting humans and other animals caused by parasitic... more...

Related Diseases for Malaria

Diseases related to Malaria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 371)
id Related Disease Score Top Affiliating Genes
1 hepatitis 30.8 IFNG IL10 TNF
2 tuberculosis 30.5 IL10 TLR9 TNF
3 dengue hemorrhagic fever 30.0 IFNG IL10 TNF
4 hepatitis b 29.9 G6PD HBB HP SLC4A1
5 plasmodium malariae malaria 12.4
6 plasmodium falciparum malaria 12.4
7 plasmodium vivax malaria 12.4
8 plasmodium ovale malaria 12.3
9 mixed malaria 12.2
10 malaria, mild 11.8
11 congenital myasthenic syndrome 11.7
12 blackwater fever 11.7
13 capillary malformation-arteriovenous malformation 11.6
14 myasthenic syndrome, congenital, 6, presynaptic 11.5
15 myasthenic syndrome, congenital, 4c, associated with acetylcholine receptor deficiency 11.4
16 myasthenic syndrome, congenital, 1a, slow-channel 11.4
17 myasthenic syndrome, congenital, 10 11.4
18 myasthenic syndrome, congenital, 5 11.4
19 myasthenic syndrome, congenital, 11, associated with acetylcholine receptor deficiency 11.3
20 megalencephaly-capillary malformation-polymicrogyria syndrome, somatic 11.3
21 myasthenic syndrome, congenital, 4a, slow-channel 11.3
22 babesiosis 11.2
23 congenital myasthenic syndrome with episodic apnea 11.2
24 schistosomiasis 11.1
25 visceral leishmaniasis 11.1
26 chiari malformation 11.0
27 chronic mountain sickness 11.0
28 chiari malformation type ii 10.9
29 hemolytic anemia due to g6pd deficiency 10.9
30 abdominal aortic aneurysm 10.9
31 congenital short bowel syndrome 10.8
32 myasthenic syndrome, congenital, 7, presynaptic 10.8
33 melanocytic nevus syndrome, congenital, somatic 10.8
34 cerebritis 10.8
35 macrophagic myofasciitis 10.7
36 intestinal pseudoobstruction, neuronal 10.7
37 pseudovaginal perineoscrotal hypospadias 10.7
38 geniculate ganglionitis 10.7 CD36 CR1 FCGR2A G6PD HBB HP
39 immunodeficiency due to defect in mapbp-interacting protein 10.7 ACKR1 CD36 CISH CR1 FCGR2A FCGR2B
40 nonspecific interstitial pneumonia 10.6 ACKR1 GYPA HP ICAM1 IFNG IL10
41 conduct disorder 10.6 ACKR1 G6PD ICAM1 IFNG IL10 TNF
42 collagenous colitis 10.6 ICAM1 IFNG IL10 NOS2 TLR9 TNF
43 cousin syndrome 10.6 CR1 FCGR2A FCGR2B ICAM1 IFNG IL10
44 pigmentation disease 10.6 HP ICAM1 IFNG IL10 TNF
45 bare lymphocyte syndrome, type i 10.6 ICAM1 IFNG IL10 NOS2 TNF
46 neurotic disorder 10.6 FCGR2A ICAM1 IFNG IL10 TNF
47 liver inflammatory pseudotumor 10.6 IFNG IL10 NOS2 TLR9 TNF
48 vagus nerve neoplasm 10.6 G6PD GYPA GYPB GYPC HBB SLC4A1
49 erythematosquamous dermatosis 10.6 IFNG IL10 NOS2 TLR9 TNF
50 erb-duchenne and dejerine-klumpke palsies 10.6 ICAM1 IFNG IL10 TNF

Graphical network of the top 20 diseases related to Malaria:



Diseases related to Malaria

Symptoms & Phenotypes for Malaria

Clinical features from OMIM:

611162

Human phenotypes related to Malaria:

56 32 (show all 16)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 myalgia 56 32 Frequent (79-30%) HP:0003326
2 fever 56 32 Very frequent (99-80%) HP:0001945
3 headache 56 32 Very frequent (99-80%) HP:0002315
4 reduced consciousness/confusion 56 32 Frequent (79-30%) HP:0004372
5 respiratory distress 56 32 Frequent (79-30%) HP:0002098
6 nausea and vomiting 56 32 Very frequent (99-80%) HP:0002017
7 cognitive impairment 56 32 Frequent (79-30%) HP:0100543
8 retinopathy 56 32 Occasional (29-5%) HP:0000488
9 anemia 56 32 Very frequent (99-80%) HP:0001903
10 gait imbalance 56 32 Frequent (79-30%) HP:0002141
11 thrombocytopenia 56 32 Frequent (79-30%) HP:0001873
12 acute kidney injury 56 32 Very frequent (99-80%) HP:0001919
13 morphological abnormality of the central nervous system 56 32 Very frequent (99-80%) HP:0002011
14 elevated c-reactive protein level 56 32 Very frequent (99-80%) HP:0011227
15 hyperbilirubinemia 56 32 Frequent (79-30%) HP:0002904
16 abnormality of blood and blood-forming tissues 56 Frequent (79-30%)

UMLS symptoms related to Malaria:


angina pectoris, chest pain, edema, fever, pruritus, remittent fever

MGI Mouse Phenotypes related to Malaria:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.21 NOS2 SLC4A1 TIRAP TLR9 TNF CD36
2 cardiovascular system MP:0005385 10.2 CD36 FCGR2B G6PD HP ICAM1 IFNG
3 cellular MP:0005384 10.17 CD36 FCGR2B G6PD HP ICAM1 IFNG
4 homeostasis/metabolism MP:0005376 10.17 SLC4A1 TIRAP TLR9 TNF ACKR1 CD36
5 immune system MP:0005387 10.1 ACKR1 CD36 CISH FCGR2A FCGR2B HP
6 digestive/alimentary MP:0005381 10.01 IFNG IL10 NOS2 TLR9 TNF CD36
7 mortality/aging MP:0010768 9.77 IFNG IL10 NOS2 SLC4A1 TIRAP TLR9
8 liver/biliary system MP:0005370 9.7 CD36 FCGR2B HP IFNG IL10 NOS2
9 renal/urinary system MP:0005367 9.17 IFNG NOS2 SLC4A1 TLR9 CD36 FCGR2B

Drugs & Therapeutics for Malaria

Drugs for Malaria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 355)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Artesunate Approved Phase 4,Phase 3,Phase 2,Phase 1 88495-63-0 6917864 5464098
2
Quinine Approved Phase 4,Phase 2,Phase 3,Phase 1 130-95-0 8549 3034034
3
Artemether Approved Phase 4,Phase 3,Phase 2,Phase 1 71963-77-4 119380 68911
4
Lumefantrine Approved Phase 4,Phase 3,Phase 2,Phase 1 82186-77-4 6437380
5
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
6
Amodiaquine Approved Phase 4,Phase 3,Phase 2,Phase 1 86-42-0 2165
7
Mefloquine Approved Phase 4,Phase 3,Phase 2,Phase 1 53230-10-7 4046
8
chloroquine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 54-05-7 2719
9
Primaquine Approved Phase 4,Phase 3,Phase 2,Phase 1 90-34-6 4908
10
Pyrimethamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 58-14-0 4993
11
Sulfadoxine Approved Phase 4,Phase 3,Phase 2,Phase 1 2447-57-6 17134
12
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1 103-90-2 1983
13
Albendazole Approved, Vet_approved Phase 4,Phase 2,Phase 3 54965-21-8 2082
14
Praziquantel Approved, Vet_approved Phase 4,Phase 3 55268-74-1 4891
15
Sulfamethoxazole Approved Phase 4,Phase 3,Phase 1,Phase 2 723-46-6 5329
16
Trimethoprim Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 738-70-5 5578
17
Efavirenz Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 154598-52-4 64139
18
Nevirapine Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 129618-40-2 4463
19
Rifampin Approved Phase 4,Phase 2,Phase 1 13292-46-1 5458213 5381226
20
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7439-89-6 23925
21
Atovaquone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 95233-18-4 74989
22
Proguanil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 500-92-5 4923
23
Hydroxychloroquine Approved Phase 4,Phase 3,Phase 2,Phase 1 118-42-3 3652
24
Azithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1 83905-01-5 55185 53477736 447043
25
Doxycycline Approved, Investigational, Vet_approved Phase 4,Early Phase 1 564-25-0 54671203
26
Copper Approved Phase 4,Phase 3 15158-11-9, 7440-50-8 27099
27
Hydroxocobalamin Approved Phase 4,Phase 3 13422-51-0 11953898 5460373 44475014
28
Selenium Approved, Vet_approved Phase 4,Phase 3 7782-49-2
29
Zinc Approved Phase 4,Phase 3,Phase 2 7440-66-6 32051 23994
30
Benzocaine Approved Phase 4,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
31
Morphine Approved, Investigational Phase 4 57-27-2 5288826
32
Dapsone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 80-08-0 2955
33
Ibuprofen Approved Phase 4 15687-27-1 3672
34
Lopinavir Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 192725-17-0 92727
35
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 155213-67-5 392622
36
Ivermectin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 70288-86-7 6474909 46936176
37
Abacavir Approved, Investigational Phase 4,Phase 3 136470-78-5 65140 441300
38
Lamivudine Approved, Investigational Phase 4,Phase 3,Early Phase 1 134678-17-4 60825
39
Zidovudine Approved Phase 4,Phase 3,Early Phase 1 30516-87-1 35370
40
Permethrin Approved, Investigational Phase 4,Phase 3 52645-53-1 40326
41
Amoxicillin Approved, Vet_approved Phase 4,Phase 3 26787-78-0 33613 2171
42
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
43
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
44
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 11103-57-4, 68-26-8 445354
45
Cyanocobalamin Approved, Nutraceutical Phase 4,Phase 3 68-19-9 44176380
46
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 1 59-67-6 938
47
Nicotinamide Approved, Nutraceutical Phase 4,Phase 3,Phase 1 98-92-0 936
48
Pyridoxal Approved, Nutraceutical Phase 4,Phase 3 66-72-8 1050
49
Pyridoxine Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 65-23-6 1054
50
Riboflavin Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 83-88-5 493570

Interventional clinical trials:

(show top 50) (show all 1091)
id Name Status NCT ID Phase
1 Intravenous Artesunate and Malaria Unknown status NCT01805232 Phase 4
2 Safety and Effectiveness of Artemisinin-based Combination Therapies (ACTs) With Repeated Treatments for Uncomplicated Falciparum Malaria Over a Three-year Period Unknown status NCT01038063 Phase 4
3 Impact of Insecticide Resistance on Vector Control Unknown status NCT01713517 Phase 4
4 Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria Unknown status NCT00902811 Phase 4
5 Effectiveness of Oral Quinine and Artemether-Lumefantrine in the Treatment of Uncomplicated Malaria in Ugandan Children Unknown status NCT00540202 Phase 4
6 Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan Unknown status NCT01178021 Phase 4
7 Evaluation of the Public Health Impact of Seasonal Intermittent Preventive Treatment (IPT) in Children in Senegal Unknown status NCT00712374 Phase 4
8 The Combined Use of Indoor Residual Spraying (IRS) and Long-lasting Insecticidal Nets (LLINs) for Malaria Prevention Unknown status NCT01697852 Phase 4
9 The Optimal Timing Of Primaquine To Prevent Malaria Transmission After Artemisinin-Combination Therapy Unknown status NCT01906788 Phase 4
10 The Effect of Paracetamol in the Treatment of Non-severe Malaria in Children in Guinea-Bissau Unknown status NCT00137566 Phase 4
11 Efficacy and Safety of Amodiaquine and Amodiaquine-Artesunate Unknown status NCT00238017 Phase 4
12 Comparison of Two Antimalarial Drugs Regimens in Patient With Plasmodium Vivax Malaria in Thailand Unknown status NCT01662700 Phase 4
13 Improving Anti-malarial Treatment Options in Guinea-Bissau - Part A Unknown status NCT01704508 Phase 4
14 Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO Unknown status NCT01930331 Phase 4
15 Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana Unknown status NCT01459146 Phase 4
16 Intermittent Antimalaria Treatment With SP in African Children Unknown status NCT00168948 Phase 4
17 Assessment of Artesunate/Mefloquine in the Peruvian Amazon Unknown status NCT02084602 Phase 4
18 Introduction of Eurartesim® in Burkina Faso, Mozambique, Ghana and Tanzania Unknown status NCT02199951 Phase 4
19 Dihydroartemisinin- Piperaquine Versus Artemether- Lumefantrine in the Treatment Uncomplicated Plasmodium Falciparum Malaria in Sudan Unknown status NCT01075945 Phase 4
20 Artemether/ Lumefantrine: A Study of the Effect of Local Food on Pharmacokinetics and Population Pharmacokinetics Unknown status NCT01944189 Phase 4
21 Evaluation of SP Resistance and Effectiveness of IPTp in Nigeria Unknown status NCT01636895 Phase 4
22 Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda Unknown status NCT00674921 Phase 4
23 Drug Interaction Between Coartem® and Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients Unknown status NCT00620438 Phase 4
24 Routine Iron Prophylaxis During Pregnancy Unknown status NCT00488579 Phase 4
25 Vitamin A Supplementation With Bacille Calmette Guerin (BCG) Vaccine Unknown status NCT00168610 Phase 4
26 Accelerating the Reduction of Malaria Transmission in Kanel, Ranérou and Linguère Districts Completed NCT02536222 Phase 4
27 ANC & Malaria Diagnostic in Pregnancy Completed NCT01703884 Phase 4
28 Restricting the Use of Artesunate Plus Amodiaquine Combination Therapy to Malaria Cases Confirmed by a Dipstick Test: A Cluster Randomised Control Trial Completed NCT00832754 Phase 4
29 The Role of Rapid Diagnostic Tests for Malaria for Targeting of ACTs at Community Level Completed NCT01907672 Phase 4
30 The Use of Homeopathic-Based Treatment Approaches to Reduce the Prevalence of Malaria in Depressed Communities Completed NCT00351013 Phase 4
31 Rapid Diagnostic Testing and Artemisinin-Based Combination Therapy for Uncomplicated Malaria by Community Health Workers Completed NCT00301015 Phase 4
32 Evaluation of the Riamet® Versus Malarone® in the Treatment of Uncomplicated Malaria Completed NCT01150344 Phase 4
33 The Synergistic Effects of Home-management and Intermittent Preventive Treatment of Malaria in Children Completed NCT00550160 Phase 4
34 Prevention of Intrauterine Growth Retardation in Burkina Faso: the Malaria Component Completed NCT00680732 Phase 4
35 Seasonal Malaria Chemoprevention Versus Home Management of Malaria in Children Under 5 Years in Ghana Completed NCT01651416 Phase 4
36 Home Management of Malaria and Pneumonia Completed NCT02151578 Phase 4
37 A Randomised Trial of Rapid Diagnostic Tests in the Diagnosis of Malaria in Tanzania Completed NCT00146796 Phase 4
38 Effect of a Combined Use of Mosquito Repellent and Insecticide Treated Net on Malaria in Ethiopia Completed NCT01160809 Phase 4
39 Improved Clinical and Microscopy Diagnosis at Primary Health Care in Tanzania Completed NCT00687895 Phase 4
40 A Community Setting Study of Malaria After Systematic Treatment of Symptomatic Carriers of P. Falciparum With COA566 (Coartem®) Completed NCT01256658 Phase 4
41 Efficacy and Cost Effectiveness of Malaria Diagnosis Procedures and the Rational Use of ACT in Zanzibar Completed NCT00549003 Phase 4
42 CQSP in Malawi: Chloroquine and Sulfadoxine-pyrimethamine Efficacy for the Treatment of Malaria in Malawi Completed NCT00125489 Phase 4
43 Efficacy of Intermittent Screening and Treatment or Intermittent Preventive Treatment (IPT) With Dihydroartemisinin-Piperaquine, Versus IPT With Sulfadoxine-Pyrimethamine for the Control of Malaria in Pregnancy in Kenya Completed NCT01669941 Phase 4
44 Impact of Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in Lampung Province, Sumatra Completed NCT01389557 Phase 4
45 Interactions Between Artemether-lumefantrine and Antiretrovirals in HIV-patients With Uncomplicated Malaria in Tanzania Completed NCT00885287 Phase 4
46 Artemether-lumefantrine (AL) Versus Artesunate + Amodiaquine (ASAQ) for the Treatment of Uncomplicated Falciparum Malaria in Burkina Faso Completed NCT01017770 Phase 4
47 Intermittent Preventive Treatment Versus Scheduled Screening and Treatment of Malaria in Pregnancy Completed NCT01084213 Phase 4
48 Prevention of Malaria With Dihydroartemisinine + Piperaquine for Forest Rangers Completed NCT02788864 Phase 4
49 In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated P. Falciparum Malaria Completed NCT02637128 Phase 4
50 The ASAP Study - Therapeutic Efficacy of Atovaquone-proguanil vs. Artesunate-atovaquone-proguanil in Cambodia Completed NCT02297477 Phase 4

Search NIH Clinical Center for Malaria

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: malaria

Genetic Tests for Malaria

Genetic tests related to Malaria:

id Genetic test Affiliating Genes
1 Susceptibility to Malaria 29

Anatomical Context for Malaria

MalaCards organs/tissues related to Malaria:

39
Testes, T Cells, Brain, Liver, Endothelial, Skin, B Cells

Publications for Malaria

Articles related to Malaria:

(show top 50) (show all 3622)
id Title Authors Year
1
Spatiotemporal epidemic characteristics and risk factor analysis of malaria in Yunnan Province, China. ( 28077125 )
2017
2
FOSL1 Inhibits Type I Interferon Responses to Malaria and Viral Infections by Blocking TBK1 and TRAF3/TRIF Interactions. ( 28049150 )
2017
3
Use of malaria RDTs in various health contexts across sub-Saharan Africa: a systematic review. ( 28521798 )
2017
4
Trimethoprim-Sulfamethoxazole Prophylaxis During Live Malaria Sporozoite Immunization Induces Long-Lived, Homologous, and Heterologous Protective Immunity Against Sporozoite Challenge. ( 28077589 )
2017
5
Role of Anopheles (Cellia) rufipes (Gough, 1910) and other local anophelines in human malaria transmission in the northern savannah of Cameroon: a cross-sectional survey. ( 28077167 )
2017
6
Comparison of Adult Mosquito Black-Light and Light-Emitting Diode Traps at Three Cowsheds Located in Malaria-Endemic Areas of the Republic of Korea. ( 28082650 )
2017
7
Monitoring of Plasmodium infection in humans and potential vectors of malaria in a newly emerged focus in southern Iran. ( 28078947 )
2017
8
Congenital Plasmodium falciparum Malaria in Washington, DC. ( 28077745 )
2017
9
Spatio-temporal analysis of malaria incidence in the Peruvian Amazon Region between 2002 and 2013. ( 28091560 )
2017
10
Clinical development of a VAR2CSA-based placental malaria vaccine PAMVAC: Quantifying vaccine antigen-specific memory B & T cell activity in Beninese primigravidae. ( 28527688 )
2017
11
Malaria mortality characterization and the relationship between malaria mortality and climate in Chimoio, Mozambique. ( 28532410 )
2017
12
Resistance to malaria through structural variation of red blood cell invasion receptors. ( 28522690 )
2017
13
Diagnosing congenital malaria in a high-transmission setting: clinical relevance and usefulness of P. falciparum HRP2-based testing. ( 28522856 )
2017
14
The Threshold of Protection from Liver-Stage Malaria Relies on a Fine Balance between the Number of Infected Hepatocytes and Effector CD8+ T Cells Present in the Liver. ( 28087668 )
2017
15
Improving local health workers' knowledge of malaria in the elimination phase-determinants and strategies: a cross-sectional study in rural China. ( 28526083 )
2017
16
Toxicity of ar-curcumene and epi-I^-bisabolol from Hedychium larsenii (Zingiberaceae) essential oil on malaria, chikungunya and St. Louis encephalitis mosquito vectors. ( 27918946 )
2017
17
Relationship between exposure to malaria and haemoglobin level of children 2-9 years old in low malaria transmission settings. ( 28522274 )
2017
18
Co-inheritance of glucose-6-phosphate dehydrogenase deficiency mutations and hemoglobin E in a Kachin population in a malaria-endemic region of Southeast Asia. ( 28531196 )
2017
19
Malaria parasite LIMP protein regulates sporozoite gliding motility and infectivity in mosquito and mammalian hosts. ( 28525314 )
2017
20
Testing times: trends in availability, price, and market share of malaria diagnostics in the public and private healthcare sector across eight sub-Saharan African countries from 2009 to 2015. ( 28526075 )
2017
21
Association of CD40L gene polymorphism with severe Plasmodium falciparum malaria in Indian population. ( 28352049 )
2017
22
Comparative analysis of the safety and tolerability of fixed-dose artesunate/amodiaquine versus artemether/lumefantrine combinations for uncomplicated falciparum malaria in pregnancy: a randomized open label study. ( 28533699 )
2017
23
Artesunate and erythropoietin synergistically improve the outcome of experimental cerebral malaria. ( 28531845 )
2017
24
Expression of cleaved caspase-3 in renal tubular cells in Plasmodium falciparum malaria patients. ( 26729581 )
2017
25
Nascent RNA sequencing reveals mechanisms of gene regulation in the human malaria parasite Plasmodium falciparum. ( 28531310 )
2017
26
Increasing the potential for malaria elimination by targeting zoophilic vectors. ( 28091570 )
2017
27
Risk of drug resistance in Plasmodium falciparum malaria therapy-a systematic review and meta-analysis. ( 28028628 )
2017
28
Direct detection of falciparum and non-falciparum malaria DNA from a drop of blood with high sensitivity by the dried-LAMP system. ( 28086864 )
2017
29
Fibrinogen domain of FREP1 is a broad spectrum malaria transmission-blocking vaccine antigen. ( 28533429 )
2017
30
Genetic and epigenetic changes in host ABCB1 influences malaria susceptibility to Plasmodium falciparum. ( 28422980 )
2017
31
High Rate of Treatment Failures in Nonimmune Travelers Treated With Artemether-Lumefantrine for Uncomplicated Plasmodium falciparum Malaria in Sweden: Retrospective Comparative Analysis of Effectiveness and Case Series. ( 27986683 )
2017
32
Using low-cost drones to map malaria vector habitats. ( 28088225 )
2017
33
Antibody profiles to wheat germ cell-free system synthesized Plasmodium falciparum proteins correlate with protection from symptomatic malaria in Uganda. ( 28089547 )
2017
34
Insecticide-treated durable wall lining (ITWL): future prospects for control of malaria and other vector-borne diseases. ( 28532494 )
2017
35
High Sporozoite Antibody Titers in Conjunction with Microscopically Detectable Blood Infection Display Signatures of Protection from Clinical Malaria. ( 28533773 )
2017
36
Plasmodium falciparum malaria co-infection with tick-borne relapsing fever in Dakar. ( 28077149 )
2017
37
The use of transgenic parasites in malaria vaccine research. ( 28525963 )
2017
38
Safety of a fixed-dose combination of artesunate and amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in real-life conditions of use in CA'te d'Ivoire. ( 28049523 )
2017
39
Age and geographic patterns of Plasmodium falciparum malaria infection in a representative sample of children living in Burkitt lymphoma-endemic areas of northern Uganda. ( 28320389 )
2017
40
Malaria Parasitemia and Parasite Density in Antiretroviral-Treated HIV-Infected Adults Following Discontinuation of Cotrimoxazole Prophylaxis. ( 28077587 )
2017
41
Evidence of non-Plasmodium falciparum malaria infection in KAcdougou, SAcnAcgal. ( 28049489 )
2017
42
The malaria testing and treatment landscape in mainland Tanzania, 2016. ( 28521811 )
2017
43
A disrupted transsulphuration pathway results in accumulation of redox metabolites and induction of gametocytogenesis in malaria. ( 28091526 )
2017
44
Multicenter Pivotal Clinical Trial of Urine Malaria Test for Rapid Diagnosis of Plasmodium falciparum Malaria. ( 27847373 )
2017
45
Malaria Pathogenesis. ( 28533315 )
2017
46
The association between malaria and malnutrition among under-five children in Shashogo District, Southern Ethiopia: a case-control study. ( 28081711 )
2017
47
The Power of Malaria Vaccine Trials Using Controlled Human Malaria Infection. ( 28081133 )
2017
48
Probability of Transmission of Malaria from Mosquito to Human Is Regulated by Mosquito Parasite Density in NaA^ve and Vaccinated Hosts. ( 28081253 )
2017
49
Placental Sequestration of Plasmodium falciparum Malaria Parasites Is Mediated by the Interaction Between VAR2CSA and Chondroitin Sulfate A on Syndecan-1. ( 27556547 )
2016
50
The Link between Plasmodium falciparum Malaria and Endemic Burkitt's Lymphoma-New Insight into a 50-Year-Old Enigma. ( 26794909 )
2016